Marketing pieces

Quote
Supernus is an OK company with some great people on the sales side. Rockville sucks. Our R&D department is a JOKE! We are exclusively an XR company. If you think you will ever present something to a doc they haven’t seen before in Psych or Neuro you’re mistaken. The only reason I’m excited about these new drugs coming is because hopefully I might get a RD position and have something new to do. I bet it won’t happen till 2021 though.
 






anonymous said:
Supernus is an OK company with some great people on the sales side. Rockville sucks. Our R&D department is a JOKE! We are exclusively an XR company. If you think you will ever present something to a doc they haven’t seen before in Psych or Neuro you’re mistaken. The only reason I’m excited about these new drugs coming is because hopefully I might get a RD position and have something new to do. I bet it won’t happen till 2021 though.
Click to expand...
I’m excited because there’s a chance I’ll get a new rd
 






anonymous said:
Sounds like the natives are getting restless. Just hold tight. I have a feeling it will be worth it. Maybe not adhd, but def impulsive aggression
Click to expand...

Impulsive aggression was the big prize and it’s never coming to market. Get your head out of your ass when is the last time you even heard it mentioned in a meeting? When that mg arm failed it was over
 






anonymous said:
Impulsive aggression was the big prize and it’s never coming to market. Get your head out of your ass when is the last time you even heard it mentioned in a meeting? When that mg arm failed it was over
Click to expand...
Man I hope not. I’ve turned down some really good jobs in hopes of making a good investment in this company. Last I heard we were supposed to hear data on phase 3 during this quarter. March is almost over and we haven’t heard anything yet. I really hope you’re wrong
 






anonymous said:
Just curious if anyone else here feels torn morally regarding our medications and the costs for them? I mean our own insurance here won’t cover these meds and the molecules are well over 20 years old. I’m someone will hop on here and call me an idiot but I can’t be the only one who feels this way. We literally sell against generic affordable medications every call, not other molecules. I think I’ll just stay in bed today.
Click to expand...
This quote is from a finance article making the rounds this month. So you’re not the only one

“Oxtellar XR and Trokendi XR are extended release formulations of oxcarbazepine and topiramate — XR stands for extended release. The underlying compounds are already marketed as generic drugs, but by creating once-daily formulations and testing them in clinical trials, Supernus is able to get pricing more like a branded drug.

Payors have not always been willing to pay the approximately $10k per year for reformulated versions of generic drugs. There is almost zero foreign demand for the company’s existing drugs. Its lead pipeline assets are more novel.

While their underlying compounds are not novel either, both are being tested in new indications and are therefore more like truly “new” drugs. There is more ingenuity going into the company’s pipeline than it has demonstrated in the past, and Supernus needs to prove that it can do more than tinker around with already-successful drugs.”
 






anonymous said:
holy shit you guys are wasted on company coolaid! This job wears on you after a while and if you don’t appreciate that then you’re on the spectrum. I get having good sales dialogue and selling our XR generics, but you have to appreciate the feeling of Groundhogs Day after a few years with these meds. I’ll continue to make my calls in the AM and focus on my other gig in the afternoons. PS- Meg is the absolute hottest!!!
Click to expand...


Who is Meg?
 






anonymous said:
This quote is from a finance article making the rounds this month. So you’re not the only one

“Oxtellar XR and Trokendi XR are extended release formulations of oxcarbazepine and topiramate — XR stands for extended release. The underlying compounds are already marketed as generic drugs, but by creating once-daily formulations and testing them in clinical trials, Supernus is able to get pricing more like a branded drug.

Payors have not always been willing to pay the approximately $10k per year for reformulated versions of generic drugs. There is almost zero foreign demand for the company’s existing drugs. Its lead pipeline assets are more novel.

While their underlying compounds are not novel either, both are being tested in new indications and are therefore more like truly “new” drugs. There is more ingenuity going into the company’s pipeline than it has demonstrated in the past, and Supernus needs to prove that it can do more than tinker around with already-successful drugs.”
Click to expand...

Whoever wrote this article should go back to work at Enterprise! Ungrateful! Just do your job and shut up.
 






anonymous said:
Whoever wrote this article should go back to work at Enterprise! Ungrateful! Just do your job and shut up.
Click to expand...
How long do you think people can be sheltered? The price you payed for talent was cheap. YOU should be grateful that you have talented people driving your business at a low cost. Maybe you should shut up and and be grateful for what you have. The fear is real!
 












anonymous said:
I agree. When was the last time we talked about mechanisms of action? Different seizure types? Want to differentiate our products from the rest? How about give us some actual scientific data in our visaid instead of all the BS. Doctors can tell when you are selective and skew the data to make our products look better. It’s an old trick. Small sample sizes and “retrospective reviews” that aren’t even close to scientifically legitimate. Why don’t we talk about the fundamental reasons our products differ from every other product on the market. Revolutionary, I know.

I guess if it doesn’t have an emoji or a flip phone, it doesn’t make the cut.
Click to expand...

^^^From November 2018.

Talk about an oldie but a goodie. Only took two years for marketing to get on board
 






Top Bottom
Back
Quote